PMID- 22146674
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20220408
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 1
IP  - 1
DP  - 2011 Oct 3
TI  - Open-label trial and randomized, double-blind, placebo-controlled, crossover 
      trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.
PG  - 24
LID - 10.1186/2045-9912-1-24 [doi]
AB  - BACKGROUND: Molecular hydrogen has prominent effects on more than 30 animal 
      models especially of oxidative stress-mediated diseases and inflammatory 
      diseases. In addition, hydrogen effects on humans have been reported in diabetes 
      mellitus type 2, hemodialysis, metabolic syndrome, radiotherapy for liver cancer, 
      and brain stem infarction. Hydrogen effects are ascribed to specific 
      radical-scavenging activities that eliminate hydroxyl radical and peroxynitrite, 
      and also to signal-modulating activities, but the detailed molecular mechanisms 
      still remain elusive. Hydrogen is a safe molecule that is largely produced by 
      intestinal bacteria in rodents and humans, and no adverse effects have been 
      documented. METHODS: We performed open-label trial of drinking 1.0 liter per day 
      of hydrogen-enriched water for 12 weeks in five patients with progressive 
      muscular dystrophy (PMD), four patients with polymyositis/dermatomyositis 
      (PM/DM), and five patients with mitochondrial myopathies (MM), and measured 18 
      serum parameters as well as urinary 8-isoprostane every 4 weeks. We next 
      conducted randomized, double-blind, placebo-controlled, crossover trial of 0.5 
      liter per day of hydrogen-enriched water or placebo water for 8 weeks in 10 
      patients with DM and 12 patients with MM, and measured 18 serum parameters every 
      4 weeks. RESULTS: In the open-label trial, no objective improvement or worsening 
      of clinical symptoms was observed. We, however, observed significant effects in 
      lactate-to-pyruvate ratios in PMD and MM, fasting blood glucose in PMD, serum 
      matrix metalloproteinase-3 (MMP3) in PM/DM, and serum triglycerides in PM/DM. In 
      the double-blind trial, no objective clinical effects were observed, but a 
      significant improvement was detected in lactate in MM. Lactate-to-pyruvate ratios 
      in MM and MMP3 in DM also exhibited favorable responses but without statistical 
      significance. No adverse effect was observed in either trial except for 
      hypoglycemic episodes in an insulin-treated MELAS patient, which subsided by 
      reducing the insulin dose. CONCLUSIONS: Hydrogen-enriched water improves 
      mitochondrial dysfunction in MM and inflammatory processes in PM/DM. Less 
      prominent effects with the double-blind trial compared to the open-label trial 
      were likely due to a lower amount of administered hydrogen and a shorter 
      observation period, which implies a threshold effect or a dose-response effect of 
      hydrogen.
FAU - Ito, Mikako
AU  - Ito M
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, 
      Japan.
FAU - Ibi, Tohru
AU  - Ibi T
AD  - Faculty of Pathophysiology and Therapeutics, Aichi Medical University College of 
      Nursing, 21 Karimata Yazako, Nagakute-cho, Aichi-gun, Aichi 480-1195, Japan.
FAU - Sahashi, Ko
AU  - Sahashi K
AD  - Department of Neurology, Aichi Medical University School of Medicine, 21 Karimata 
      Yazako, Nagakute-cho, Aichi-gun, Aichi 480-1195, Japan.
FAU - Ichihara, Masashi
AU  - Ichihara M
AD  - Department of Biomedical Sciences, College of Life and Health Sciences, Chubu 
      University, 1200 Matsumoto, Kasugai, Aichi 487-8501, Japan.
FAU - Ito, Masafumi
AU  - Ito M
AD  - Department of Longevity and Aging Research, Gifu International Institute of 
      Biotechnology, 1-1 Nakafudogaoka, Kakamigahara, Gifu 504-0838, Japan.
FAU - Ohno, Kinji
AU  - Ohno K
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20111003
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
PMC - PMC3231939
EDAT- 2011/12/08 06:00
MHDA- 2011/12/08 06:01
PMCR- 2011/10/03
CRDT- 2011/12/08 06:00
PHST- 2011/06/24 00:00 [received]
PHST- 2011/10/03 00:00 [accepted]
PHST- 2011/12/08 06:00 [entrez]
PHST- 2011/12/08 06:00 [pubmed]
PHST- 2011/12/08 06:01 [medline]
PHST- 2011/10/03 00:00 [pmc-release]
AID - 2045-9912-1-24 [pii]
AID - 10.1186/2045-9912-1-24 [doi]
PST - epublish
SO  - Med Gas Res. 2011 Oct 3;1(1):24. doi: 10.1186/2045-9912-1-24.